Patient‐reported outcomes following treatment with the human GLP‐1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes

201075 citationsJournal Articlebronze Open Access

Authors

Bruce W. Bode · Atlanta Diabetes Associates

Marcia A. Testa · Harvard University

Melissa Magwire · Shawnee Mission Medical Center

Paula M. Hale · Novo Nordisk (United States)

Mette Hammer · Novo Nordisk (Denmark)

Lawrence Blonde · Ochsner Medical Center

A. J. Garber ·

Abstract

Improved glycaemic control and decreased weight with liraglutide 1.8 mg vs. glimepiride can improve psychological and emotional well-being and health perceptions by reducing anxiety and worry associated with weight gain.

Topics & Keywords

Diabetes Treatment and Management Diabetes Management and Research Metabolism, Diabetes, and Cancer

Publication Details

Published in: Diabetes Obesity and Metabolism

Volume 12, Issue 7, pp. 604-612

DOI: 10.1111/j.1463-1326.2010.01196.x

Field-Weighted Citation Impact: 4.81

Command Palette

Patient‐reported outcomes following treatment with the human GLP‐1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes

Authors

Abstract

Topics & Keywords

Publication Details